You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 17, 2024

HUMIRA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for HUMIRA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Janssen Research & Development, LLCPhase 1
Samsung Bioepis Co., Ltd.Phase 4
Prestige Biopharma LtdPhase 1

See all HUMIRA clinical trials

Recent Litigation for HUMIRA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Hetero USA, Inc.2023-11-20
Janssen Biotech, Inc. v. Amgen Inc.2022-11-29
AMGEN INC. v. APOTEX INC.2022-06-14

See all HUMIRA litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2019-09-17
2017-12-20
Sandoz Inc.2017-11-06

See all HUMIRA litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMIRA Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications
Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Patent Expiration
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 28, 2017 ⤷  Sign Up 3031-03-31
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 28, 2017 ⤷  Sign Up 2027-04-04
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 28, 2017 ⤷  Sign Up 2027-04-04
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 21, 2017 ⤷  Sign Up 2027-04-04
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 21, 2017 ⤷  Sign Up 2025-11-04
Abbvie Inc. HUMIRA adalimumab Injection 125057 October 17, 2016 ⤷  Sign Up 2028-10-06
Abbvie Inc. HUMIRA adalimumab Injection 125057 October 17, 2016 ⤷  Sign Up 2027-04-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Patent Expiration

2) High Certainty: US Patents for HUMIRA Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HUMIRA Derived from Patent Text Search

These patents were obtained by searching patent claims

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.